Anal cancer
Human papillomavirus–attributable cancers in the United States, 2012–2016
Human papillomavirus ( HPV ) causes nearly all cervical cancers and some cancers of the vagina, vulva, penis, anus, and...
Antibiotics exposure linked to increased colon cancer risk
In an extensive data mining analysis of British medical records, researchers at the Johns Hopkins Kimmel Cancer Center have concluded...
European Commission has approved Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer
The European Commission has approved Tecentriq ( Atezolizumab ) plus chemotherapy ( Abraxane [ Paclitaxel protein-bound particles for injectable suspension...
Nubeqa for non-metastatic castration-resistant prostate cancer, approved by FDA
The Food and Drug Administration ( FDA ) has approved Nubeqa ( Darolutamide ) for non-metastatic castration-resistant prostate cancer. Approval was...
Triple-negative breast cancer: Pembrolizumab in combination with chemotherapy has met primary endpoint of pathological complete response in phase 3 KEYNOTE-522 trial
The phase 3 KEYNOTE-522 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has met one...
Direct-acting antivirals reduce risk of premature mortality and liver cancer for patients with chronic hepatitis C
The first prospective, longitudinal study investigating treatment of chronic hepatitis C with direct-acting antivirals finds that the treatment is associated...
Hyperprogressive disease in advanced non–small cell lung cancer patients treated with immune checkpoint inhibitors
Hyperprogressive disease ( HPD ) is a paradoxical boost in tumour growth described in a subset of cancer patients treated...
Pembrolizumab in combination with chemotherapy has improved overall survival versus chemotherapy alone as first-line treatment for patients with advanced NSCLC whose tumors do not express PD-L1
The first-line treatment with Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has demonstrated improvements in overall...
Hyperprogressive disease in early-phase immunotherapy trials: clinical predictors and association with immune-related toxicities
A subset of patients treated with immune checkpoint inhibitors experience an accelerated tumor growth rate ( TGR ) in comparison...
Diabetes mellitus: risk of heart failure more in women than men
Diabetes confers a greater excess risk of heart failure in women than men, according to new research in Diabetologia, the...
Vitrakvi is the first tissue-agnostic cancer drug approved in European Union
The European Commission has granted marketing authorization in the European Union ( EU ) for the precision oncology treatment Vitrakvi...
MONALEESA-3 trial of postmenopausal patients with HR+, HER2- advanced breast cancer treated with Fulvestrant plus Ribociclib
The phase III MONALEESA-3 trial investigated Ribociclib, a cyclin-dependent kinase 4/6 ( CDK4/6 ) inhibitor, plus Fulvestrant as first-line...
MONARCH 2: overall survival of Abemaciclib plus Fulvestrant in patients with HR+, HER2- advanced breast cancer
Abemaciclib ( Verzenios ) is an oral, selective cyclin-dependent kinase 4 & 6 inhibitor, approved for hormone receptor-positive ( HR+...
Xospata as a monotherapy for patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation, approved in European Union
The European Commission ( EC ) has approved the oral once-daily therapy Xospata ( Gilteritinib ) as a monotherapy for...
Enfortumab Vedotin in combination with immune therapy Pembrolizumab as first-line treatment for advanced bladder cancer
Initial results from the phase 1 clinical trial EV-103 were announced. Forty-five patients were evaluated for safety with the combination...
Bavencio plus Axitinib combination for first-line treatment of patients with advanced renal cell carcinoma, approved in European Union
The European Commission ( EC ) has approved Bavencio ( Avelumab ) in combination with Axitinib ( Inlyta ) for...
Keytruda as first-line treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma: two new regimens approved by European Commission
The European Commission ( EC ) has approved Keytruda , an anti-PD-1 therapy, as monotherapy or in combination with Platinum...
Calquence approved by FDA for adult patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma
Tthe US Food and Drug Administration ( FDA ) has approved Calquence ( Acalabrutinib ) for adult patients with chronic...
Osteoarthritis: significant improvement in pain and physical function with Tanezumab
Results from a phase 3 study evaluating Tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis ( OA...
Combined modality treatment associated with improved overall survival in pediatric Hodgkin lymphoma patients
Research from Rutgers Cancer Institute of New Jersey ( Unined States ) has shown improved overall survival at five years...